Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diseases of the Thyroid

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 25 articles: HTML format

Single Articles

April 2024
1. READ ML, Brookes K, Zha L, Manivannan S, et al
   Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
   Clin Cancer Res. 2024;30:1352-1366.
   PubMed     Abstract available
   
   
   January 2024
2. LECHNER MG, Brent GA
   A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
   Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
   PubMed     Abstract available
   
   
   December 2023
3. KIM YH, Yoon SJ, Kim M, Kim HH, et al
   Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
   Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
   PubMed     Abstract available
   
   
   November 2023
4. SHEN C, Shi X, Wen D, Zhang Y, et al
   Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
   Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
   PubMed     Abstract available
   
   
   October 2023
5. FU H, Huang J, Zhao T, Wang H, et al
   Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
   Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
   PubMed     Abstract available
   
   
   September 2023
6. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
   FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
   Clin Cancer Res. 2023;29:3573-3578.
   PubMed     Abstract available
   
   
   August 2023
7. CHI Y, Zheng X, Zhang Y, Shi F, et al
   Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
   Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
   PubMed     Abstract available
   
   
   June 2023
8. HU H, Ng TSC, Kang M, Scott E, et al
   Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
   Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
   PubMed     Abstract available
   
   
   
9. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
   Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
   Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
   PubMed     Abstract available
   
   
   May 2023
10. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 May 16:CCR-23-0278. doi: 10.1158/1078-0432.CCR-23-0278.
    PubMed     Abstract available
    
    
    
11. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    PubMed     Abstract available
    
    
    April 2023
12. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    PubMed     Abstract available
    
    
    February 2023
13. BOUCAI L, Saqcena M, Kuo F, Grewal RK, et al
    Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy.
    Clin Cancer Res. 2023 Feb 13:CCR-22-2882. doi: 10.1158/1078-0432.CCR-22-2882.
    PubMed     Abstract available
    
    
    October 2022
14. CABANILLAS ME, Busaidy NL, Sherman SI
    Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
    Clin Cancer Res. 2022;28:4164-4166.
    PubMed     Abstract available
    
    
    June 2022
15. DUKE ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Clin Cancer Res. 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
    PubMed     Abstract available
    
    
    May 2022
16. WEBER M, Kersting D, Riemann B, Brandenburg T, et al
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Clin Cancer Res. 2022 May 20. pii: 699089. doi: 10.1158/1078-0432.CCR-22-0437.
    PubMed     Abstract available
    
    
    July 2021
17. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    PubMed     Abstract available
    
    
    
18. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available
    
    
    June 2021
19. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available
    
    
    May 2021
20. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available
    
    
    April 2021
21. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available
    
    
    December 2020
22. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available
    
    
    November 2020
23. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available
    
    
    October 2020
24. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available
    
    
    April 2020
25. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.